The liability, safety, and accuracy questions underlying one creative proposal, in this week's AI Prognosis newsletter.
Novo Nordisk is set to soon unveil pivotal Phase 3 data on whether semaglutide — the blockbuster GLP-1 drug behind Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback